Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Oskar Marín-Béjar(Institut d'Investigació Biomédica de Bellvitge), Jean‐Christophe Marine(VIB-KU Leuven Center for Cancer Biology), Michael Dewaele(KU Leuven), Jonas Demeulemeester(The Francis Crick Institute), Francesca M. Bosisio(Universitair Ziekenhuis Leuven), Eleonora Leucci(VIB-KU Leuven Center for Cancer Biology), Mitchell P. Levesque(Duke University), Thierry Voet(Wellcome Sanger Institute), Florian Rambow(Essen University Hospital), Nina Van Raemdonck(VIB-KU Leuven Center for Cancer Biology), Joanna Poźniak(VIB-KU Leuven Center for Cancer Biology), Julia Femel(Miltenyi Biotec (Germany)), Panagiotis Karras(VIB-KU Leuven Center for Cancer Biology), Helen Rizos(Macquarie University), Amanda W. Lund(New York University), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Dennis Pedri(VIB-KU Leuven Center for Cancer Biology), Toon Swings, Isabelle Vanden Bempt(KU Leuven), Joost J. van den Oord(KU Leuven), Greet Bervoets(VIB-KU Leuven Center for Cancer Biology), Stefan Lehnert(KU Leuven), Oliver Bechter(Universitair Ziekenhuis Leuven), Sara Vander Borght(Universitair Ziekenhuis Leuven), Aljosja Rogiers(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 154
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Methods and applications for single-cell and spatial multi-omics
|Nature Reviews Genetics|2023|1.1k
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
|Nature|2013|735
Melanoma addiction to the long non-coding RNA SAMMSON
|Nature|2016|588